Blood tests for Alzheimer’s disease are now so accurate that a positive result, on its own, is reason enough for people who are suspected of having AD to start immunotherapy. So proffered Suzanne ...

The therapeutic antibody lecanemab has been in clinical use in the U.S. for two years, and doubts about whether it would be feasible for clinics to implement and manage this therapy have eased. Even ...

Phospho-tau217 has emerged as an excellent marker of the presence of amyloid pathology in the brain, but for markers of neurofibrillary tangles, fragments of tau’s microtubule binding region have a ...

Back in mid-June, Alzforum reported on how the AD research field was being buffeted by cuts in funding to the National Institutes of Health (Jun 2025 news; Jun 2025 news). At the time, scientists felt ...

At this year’s Alzheimer’s Association International Conference, held July 27-31 in Toronto, scientists introduced a plethora of new assays for biomarkers that could improve diagnosis and tracking of ...

The Dominantly Inherited Alzheimer Network has been at the vanguard of AD immunotherapy development, launching the first secondary and primary prevention trials, as well as the first study of ...

Lithium is one of the oldest drugs in psychiatric medicine, commonly prescribed for bipolar disorder. Now, a study in the August 6 Nature lays out a new case for the potential use of this metal ...

Summary The Thy1-αSyn mouse model, a.k.a. Line 61, overexpresses human α-synuclein under the Thy1 promoter (Rockenstein et al., 2002). It is one of the most extensively characterized animal models of ...

Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected] ...

03 October 2025 DOWNLOAD TO YOUR CALENDAR Dublin, Ohio and Online View Conference Website ...

Part 1 of 6: Chicago—ALS Database Opens for Business Part 2 of 6: Chicago—ALS Protein SOD1 Painted as Disease Template Part 3 of 6: Chicago—ALS Clinical Trials: New Hope After Phase 3 Setbacks Part 4 ...